Comment
doi: 10.1016/S2352-3018(21)00269-1.
Epub 2021 Oct 14.
Reassessing oral lead-in for injectable long-acting HIV therapy
Affiliations
- PMID: 34656209
- DOI: 10.1016/S2352-3018(21)00269-1
Item in Clipboard
Comment
Reassessing oral lead-in for injectable long-acting HIV therapy
Lancet HIV.
2021 Nov.
No abstract available
Conflict of interest statement
JML reports consulting honoraria from ViiV Healthcare, Gilead Sciences and Janssen-Cila; and research grants from Gilead Sciences and ViiV Healthcare. PES has served on advisory boards and received grants and personal fees from Gilead, ViiV Healthcare, Janssen, and Merck.
Comment on
-
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14. Lancet HIV. 2021. PMID: 34656207 Clinical Trial.
Similar articles
-
Use of long-acting injectable antiretroviral agents for human immunodeficiency Virus: A review.J Clin Virol. 2022 Jan;146:105032. doi: 10.1016/j.jcv.2021.105032. Epub 2021 Nov 23. J Clin Virol. 2022. PMID: 34883407 Review.
-
Long-acting injectable for HIV approved for use in the UK.Lancet Infect Dis. 2022 Jan;22(1):26. doi: 10.1016/S1473-3099(21)00775-1. Lancet Infect Dis. 2022. PMID: 34953553 No abstract available.
-
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).J Infect Dis. 2016 Mar 15;213(6):1013-7. doi: 10.1093/infdis/jiv528. Epub 2015 Nov 12. J Infect Dis. 2016. PMID: 26563240
-
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
-
Long-acting drugs and formulations for the treatment and prevention of HIV infection.Int J Antimicrob Agents. 2021 Jan;57(1):106220. doi: 10.1016/j.ijantimicag.2020.106220. Epub 2020 Nov 6. Int J Antimicrob Agents. 2021. PMID: 33166693 Free PMC article. Review.
Cited by
-
PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee.Int J Environ Res Public Health. 2025 Apr 23;22(5):662. doi: 10.3390/ijerph22050662. Int J Environ Res Public Health. 2025. PMID: 40427779 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
